Last reviewed · How we verify
AZD2816
AZD2816 is a small molecule inhibitor of the PI3K delta subunit.
AZD2816 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | AZD2816 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, AZD2816 is thought to modulate the immune response and potentially treat various diseases. This mechanism is being explored in the context of AZD2816's development for certain types of cancer.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL)
Common side effects
- Neutropenia
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2816 CI brief — competitive landscape report
- AZD2816 updates RSS · CI watch RSS
- AstraZeneca portfolio CI